CIK 0000882361
APTO Aptose Biosciences Inc.
Insider trading from SEC Form 4. Last filing Jul 2, 2026.
In brief
Aptose Biosciences Inc. (APTO) has 19 SEC Form 4 filings on file from 8 insiders, the latest filed on Jul 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at APTO. The newest: William G. Rice (Chair, President & CEO) bought $20k of stock on Nov 25, 2024, filed Nov 26, 2024, scored 28 (weak).
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Signals
Open-market buys and sells at Aptose Biosciences Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | William G. Rice Chair, President & CEO buy | $20k 100,000 shares | +19% | - |
Transactions
The newest 50 of 84 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Bernd R. Seizinger other | DDisposition to issuer Common Shares | -17,000 | $1.72 | $29k | 0 | Jul 2, 2026 |
| Jun 30, 2026 | Bernd R. Seizinger other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -3,333 | $0.00 | $0 | 0 | Jul 2, 2026 |
| Jun 30, 2026 | Bernd R. Seizinger other | DDisposition to issuer Stock Option (right to buy)derivative | -100,000 | $0.00 | $0 | 0 | Jul 2, 2026 |
| Jun 30, 2026 | Bernd R. Seizinger other | DDisposition to issuer Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 2, 2026 |
| Jun 30, 2026 | Denis R Burger other | DDisposition to issuer Common Shares | -70 | $1.72 | $120 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | William G. Rice Chair, President & CEO | DDisposition to issuer Common Shares | -613,252 | $1.72 | $1.1M | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Warren Whitehead other | DDisposition to issuer Common Shares | -33 | $1.72 | $57 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Fletcher Payne Sr VP and CFO | DDisposition to issuer Common Shares | -222 | $1.72 | $382 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Rafael Bejar Sr VP & Chief Medical Officer | DDisposition to issuer Common Shares | -244 | $1.72 | $420 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Erich Platzer other | DDisposition to issuer Common Shares | -1,122 | $1.72 | $1,930 | 0 | Jul 1, 2026 |
| Jun 13, 2026 | Mark D. Vincent other | DDisposition to issuer Common Shares | -14 | $1.72 | $24 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | William G. Rice Chair, President & CEO | DDisposition to issuer Employee Stock Option ("Right to Buy")derivative | -70,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Denis R Burger other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -3,333 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Fletcher Payne Sr VP and CFO | DDisposition to issuer Common Sharesindirect: Fletcher Payne 2019 Trust | -22 | $1.72 | $38 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Erich Platzer other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -3,333 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Mark D. Vincent other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -3,333 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Rafael Bejar Sr VP & Chief Medical Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -35,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Warren Whitehead other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -3,333 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | William G. Rice Chair, President & CEO | DDisposition to issuer Warrantsderivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Warren Whitehead other | DDisposition to issuer Director Option Grantderivative | -100,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Denis R Burger other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -100,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Fletcher Payne Sr VP and CFO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -55,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Mark D. Vincent other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -100,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Erich Platzer other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -100,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Rafael Bejar Sr VP & Chief Medical Officer | DDisposition to issuer Employee Stock Optionderivative | -200,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Warren Whitehead other | DDisposition to issuer Director Option Grantderivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Mark D. Vincent other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Rafael Bejar Sr VP & Chief Medical Officer | DDisposition to issuer Performance Stock Optionderivative | -400,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | William G. Rice Chair, President & CEO | DDisposition to issuer Employee Stock Option ("Right to Buy")derivative | -400,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Fletcher Payne Sr VP and CFO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -200,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Denis R Burger other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Erich Platzer other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Mark D. Vincent other | DDisposition to issuer Director Option Grantderivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | William G. Rice Chair, President & CEO | DDisposition to issuer Performance Stock Optionsderivative | -600,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Warren Whitehead other | DDisposition to issuer Director Option Grantderivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Denis R Burger other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Rafael Bejar Sr VP & Chief Medical Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -343,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Fletcher Payne Sr VP and CFO | DDisposition to issuer Common Stock (Option)derivative | -1,000,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Erich Platzer other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Denis R Burger other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Mark D. Vincent other | DDisposition to issuer Director Option Grantderivative | -154,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | William G. Rice Chair, President & CEO | DDisposition to issuer Employee Option Grantderivative | -700,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Warren Whitehead other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Rafael Bejar Sr VP & Chief Medical Officer | DDisposition to issuer Employee Option Grantderivative | -200,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Erich Platzer other | DDisposition to issuer Director Option Grantderivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | William G. Rice Chair, President & CEO | DDisposition to issuer Employee Stock Option ("Right to Buy")derivative | -343,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Warren Whitehead other | DDisposition to issuer Director Option Grantderivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Mark D. Vincent other | DDisposition to issuer Stock Options (Right to Buy)derivative | -40,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Denis R Burger other | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -160,334 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | Erich Platzer other | DDisposition to issuer Director Option Grantderivative | -135,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
50 of 84 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Denis R Burgerother, director
- Rafael BejarSr VP & Chief Medical Officer
- Erich Platzerother, director
- Fletcher PayneSr VP and CFO
- William G. RiceChair, President & CEO
- Bernd R. Seizingerdirector, other
- Mark D. Vincentother, director
- Warren Whiteheadother, director
Questions about APTO
Answered from the filings on this page, as of the latest one.
Are insiders buying APTO?
No. In the last 90 days no insider at Aptose Biosciences Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade APTO on the open market?
William G. Rice (Chair, President & CEO) bought $20k of APTO on Nov 25, 2024 and filed the Form 4 on Nov 26, 2024. InsiderTell scored 28 (weak).
How many insiders file Form 4 at Aptose Biosciences Inc.?
8 people have filed a Form 4 at Aptose Biosciences Inc., among them Denis R Burger (director), Rafael Bejar (Sr VP & Chief Medical Officer), Erich Platzer (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.